Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 429

1.

Generic substitution of antihypertensive drugs: does it affect adherence?

Van Wijk BL, Klungel OH, Heerdink ER, de Boer A.

Ann Pharmacother. 2006 Jan;40(1):15-20. Epub 2005 Nov 22.

PMID:
16303985
2.

Society already achieves economic benefits from generic substitution but fails to do the same for therapeutic substitution.

Gumbs PD, Verschuren WM, Souverein PC, Mantel-Teeuwisse AK, de Wit GA, de Boer A, Klungel OH.

Br J Clin Pharmacol. 2007 Nov;64(5):680-5. Epub 2007 Sep 13.

3.

Initial non-compliance with antihypertensive monotherapy is followed by complete discontinuation of antihypertensive therapy.

Van Wijk BL, Klungel OH, Heerdink ER, de Boer A.

Pharmacoepidemiol Drug Saf. 2006 Aug;15(8):587-93.

PMID:
16586465
4.

Generic and therapeutic statin switches and disruptions in therapy.

Chapman RH, Benner JS, Girase P, Benigno M, Axelsen K, Liu LZ, Nichol MB.

Curr Med Res Opin. 2009 May;25(5):1247-60. doi: 10.1185/03007990902876271 .

PMID:
19344292
5.

Association between hospitalization and discontinuity of medication therapy used in the community setting in the Netherlands.

Stuffken R, Heerdink ER, de Koning FH, Souverein PC, Egberts AC.

Ann Pharmacother. 2008 Jul;42(7):933-9. doi: 10.1345/aph.1L062. Epub 2008 Jun 10.

PMID:
18544655
6.

Generic substitution: additional challenge for adherence in hypertensive patients?

Håkonsen H, Eilertsen M, Borge H, Toverud EL.

Curr Med Res Opin. 2009 Oct;25(10):2515-21. doi: 10.1185/03007990903192223.

PMID:
19708764
7.

The association between compliance with antihypertensive drugs and modification of antihypertensive drug regimen.

Van Wijk BL, Klungel OH, Heerdink ER, de Boer A.

J Hypertens. 2004 Sep;22(9):1831-7.

PMID:
15311113
8.

[Evaluation of efficacy and safety of manidipine hydrochloride among essential hypertensive patients: Substitution from branded product (Calslot) to Generic Product (Manidip)].

Kobayashi H, Obara T, Takahashi N, Takahashi T, Igari Y, Oikawa T, Saito S, Ohkubo T, Imai Y, Takahashi M.

Yakugaku Zasshi. 2007 Dec;127(12):2045-50. Japanese.

9.

Brand substitution or multiple switches per patient? An analysis of pharmaceutical brand substitution in Australia.

Kalisch LM, Roughead EE, Gilbert AL.

Pharmacoepidemiol Drug Saf. 2008 Jun;17(6):620-5. doi: 10.1002/pds.1580.

PMID:
18324613
10.

Norwegian patients on generic antihypertensive drugs: a qualitative study of their own experiences.

Toverud EL, Røise AK, Hogstad G, Wabø I.

Eur J Clin Pharmacol. 2011 Jan;67(1):33-8. doi: 10.1007/s00228-010-0935-x. Epub 2010 Nov 23.

11.

Rate and determinants of 10-year persistence with antihypertensive drugs.

Van Wijk BL, Klungel OH, Heerdink ER, de Boer A.

J Hypertens. 2005 Nov;23(11):2101-7.

PMID:
16208154
12.

Evaluation of the clinical and economic impact of a brand name-to-generic warfarin sodium conversion program.

Witt DM, Tillman DJ, Evans CM, Plotkin TV, Sadler MA.

Pharmacotherapy. 2003 Mar;23(3):360-8.

PMID:
12627935
13.
15.

[Influence of substitution of brand name for generic drugs on therapeutic compliance in hypertension and dyslipidemia].

Mainar AS, Artieda RN.

Gac Sanit. 2010 Nov-Dec;24(6):473-82. doi: 10.1016/j.gaceta.2010.07.007. Epub 2010 Oct 20. Spanish.

16.

Impact of the Minimum Pricing Policy and introduction of brand (generic) substitution into the Pharmaceutical Benefits Scheme in Australia.

McManus P, Birkett DJ, Dudley J, Stevens A.

Pharmacoepidemiol Drug Saf. 2001 Jun-Jul;10(4):295-300.

PMID:
11760489
17.

Resource use and cost implications of switching among warfarin formulations in atrial fibrillation patients.

Kwong WJ, Kamat S, Fang C.

Ann Pharmacother. 2012 Dec;46(12):1609-16. doi: 10.1345/aph.1Q472. Epub 2012 Nov 13.

PMID:
23150608
18.

First-year treatment adherence among outpatients initiating antihypertensive medication in Korea: results of a retrospective claims review.

Sung SK, Lee SG, Lee KS, Kim DS, Kim KH, Kim KY.

Clin Ther. 2009 Jun;31(6):1309-20. doi: 10.1016/j.clinthera.2009.06.011.

PMID:
19695396
19.

Evaluation of an interchangeability switch in patients treated with clozapine: A retrospective review.

Alessi-Severini S, Honcharik PL, Simpson KD, Eleff MK, Collins DM.

J Clin Psychiatry. 2006 Jul;67(7):1047-54.

PMID:
16889447
20.

Generic switch after ramipril patent expiry is not associated with decreased pharmacy refill compliance: a retrospective study using the DAPI database.

Ude M, Schuessel K, Quinzler R, Leuner K, Müller WE, Schulz M.

J Hypertens. 2011 Sep;29(9):1837-45. doi: 10.1097/HJH.0b013e32834942be.

PMID:
21738055
Items per page

Supplemental Content

Write to the Help Desk